RTI Realomics: Leveraging Multi-Omic Insights to Identify Precision Therapy Opportunities

The RTI Realomics™ platform empowers researchers and scientists to accelerate therapeutic discovery by integrating and analyzing complex multi-omic datasets. Designed to streamline drug repurposing workflows, Realomics enables users to scan multiple drug repurposing databases simultaneously to create a more comprehensive view of the drug repurposing landscape and generating dynamic reports of approved compounds that align with user-supplied genome-wide evidence.

Using an interactive interface, users can seamlessly integrate evidence within and across multiple omic domains to prioritize genes and identify compounds that target these prioritized genes, empowering them to make informed data-driven decisions, all within a single platform. Additionally, users have the option to explore investigational compounds currently in clinical trials or experimental compounds in pre-clinical stages. They can select their preferred level of clinical development, tailoring the experience to their specific research interests.

Integrating multi-omic datasets proved to be challenging due to data volume, varying standardization methods, and experimental heterogeneity. Robust gene prioritization and intelligent drug repurposing requires a careful balance between modality-specific insights and holistic, cross-omic analysis. Furthermore, fragmented and time-consuming queries of existing resources, often reliant on manual database searches and disconnected tools, hinder efficient preparation for expert consultations.

Recognizing this gap, the Realomics team set out to build a platform that would unify these steps into a single, intuitive experience. The goal was to create a tool that could ingest a range of common file formats, automate integration across omic layers, and present results through an interactive interface that supported robust user-driven prioritization. What began as a prototype quickly demonstrated its value across RTI projects, helping researchers accelerate the translation of scientific discovery into potential clinical strategies through extracting meaningful insights from complex biological data. Today, Realomics is a growing part of RTI’s digital product portfolio, enabling more efficient and impactful translational research.

RTI Realomics™ is designed to streamline the drug repurposing process by integrating diverse data sources and providing powerful analytical tools.

• Data Ingestion: Ingests multiple common file formats, including comma and tab-delimited files (.csv and .tsv/.txt), allowing for flexible input of data.
• Interactive Search and Prioritization: Enables users to search and prioritize results based on their specific guidance through an intuitive interface.
• Multi-Omic Integration: Integrates gene-level data from various multi-omic molecular profiles, including genomic, transcriptomic, proteomic, and metabolomic datasets.
• Comprehensive Knowledge Base Consolidation: Consolidates up-to-date information from multiple drug and target knowledgebases, such as Open Targets, Pharos, and the Therapeutic Target Database (TTD).
• Gene Association Identification: Identifies genes associated with specific indications through analysis across multiple lines of omic evidence, enhancing the understanding of their roles in disease contexts.

In the dynamic field of biomedical research, the search for effective treatments often involves navigating a complex landscape of drug databases and pharmacological information. Drug repurposing can significantly reduce the time between discovery science and clinical use, and therapies with genetically supported targets associated with diseases succeed in clinical trials two to three times more than those without clinical support. Therefore, efficiently identifying potential drug candidates is essential for accelerating the translation of scientific discoveries into practical therapies.

Advantages of a unified platform include:

• Comprehensive: Querying multiple databases provide a more comprehensive view of the drug repurposing landscape.
• Efficiency: Automated simultaneous querying across databases saves time and enhances productivity.
• Data-Driven Decision Making: Integrates multi-omic datasets to help identify prioritized genes associated with diseases and the compounds that target them.
• Supports Drug Repurposing: Facilitates the identification of existing drugs that can be more quickly repurposed for new therapeutic uses.
• Data Integration: Consolidates overlapping and unique information from various drug-related resources for a holistic view.
• Structured Insights: Generates dynamic reports on potential compound-gene pairings and supporting evidence, streamlining expert review.
• Interactive User-Friendly Interface: Provides a flexible interface for tailored queries and exploration of investigational compounds.
• Improves Reproducibility: Standardizes queries across resources, improving reproducibility.
• Robust Validation: Increases the probability of true positives, reducing the time needed for follow-up to rule out false positives.

The RTI Realomics platform is specifically designed for the general research audience working to quickly translate biological discovery into clinical practice. This includes academic researchers and institutions focused on genomics and multi-omic studies. Additionally, small biotechnology firms seeking to leverage existing drugs for new indications will find immense value in Realomics' capability to integrate multi-omic cellular profiles and facilitate data-driven decision-making. Overall, the platform targets professionals aiming to differentiate their research, effectively manage complex datasets, and expedite the translation of discoveries into viable therapeutic strategies.